RIW: Best Poster Student Travel
JSM: Best Paper Best Poster Best Student Paper
NCB: Best Paper Best Student Poster
Scholarship Award
2023
- Ying Cui, Emory University, Biostatistics
- Robert Tumasian, Columbia University, Mailman School of Public Health, Biostatistics
- Shanta Ghosh, University of Illinois Chicago, Public health-Biostatistics
- Emily Getzen, University of Pennsylvania, Biostatistics
- Jerry Chang, Harvard T.H. Chan School of Public Health, Biostatistics
- Dominique McDaniel, Drexel University, Biostatistics
- Cole Manschot, North Carolina State University, Statistics
- MaryLena Bleile, Southern Methodist University, Biostatistics
2022
- Larry Han, Harvard University
- Sasha Kravets, University of Illinois at Chicago
- Lianlian Du, University of Wisconsin
- Chenqi Fu, Pennsyvlania State University
2021
- Siddhesh Kulkarni, University of Louisville
- Ruizhe Chen, University of Illinois at Chicago
- Michael Lucagbo, University of Maryland
- Inkoo Lee, Florida State University
- Mian Arif Shams Adnan, Bowling Green State University
2020
- Bryan Blette (UNC, Chapel Hill)
- Yan Gao (Univ Illinois, Chicago)
- Yunasa Olufadi (Univ Memphis)
- Liwen Wu (Univ Pittsburgh)
- Xiao Wu (Harvard)
2019
- Busola Ololade Sanusi, UNC-Chapel Hill
- Laura Elizabeth (Beth) Wiener, UNC-Chapel Hill
- Nina Zhou, University of Michigan Ann Arbor
2018
- Christopher R. Barbour, Montana State University
- Thevaa Chandereng, University of Wisconsin at Madison
- Will A. Eagan, Purdue University
Best Poster Award at Regulatory-Industry Statistics Workshop
2019
- First: Yong Lin, Zhen Zhang, Jingyi Liu, Eli Lilly and Company, Probability of Study Success (PrSS) Evaluation Based on Multiple Endpoints in Immuno-Oncology (IO)
- Second: Guanglei Yu, Yuanyuan Bian, Margaret Gamalo-Siebers, Eli Lilly and Company, Entropy Balance Weighting and Power Priors: Its use in Real World Data (RWD) and Disproportionate Randomized-Controlled Trials (RCTs)
- Third: Nadeesri Wijekoon, Oluwatobi Aduroja, Jessica M. Biggs, Megan Ehret, Vijay Ivaturi, Dina El-Metwally, Mathangi Gopalakrishnan,University of Maryland, Baltimore County, Model-Based Approach to Optimize Clinical Outcomes in Neonatal Opioid Withdrawal Syndrome using Real World Data
2018
- First: Koko Asakura, National Cerebral and Cardiovascular Center, Toshimitsu Hamasaki, National Cerebral and Cardiovascular Center, & Scott R. Evans, Harvard School of Public Health, Interim monitoring for futility in clinical trials with co-primary endpoints
- Second: Caimiao Wei, Satrajit Roychoudhury, Pfizer Inc, Co-development of Multiple Drug Combinations in Oncology: A Bayesian Design for Dose Finding
- Third: Dongyuan Xing, Jane Wu, Matthew Guo, Eisai Inc. Considerations on Group Sequential Design for Multiple Endpoints with Different Information Fractions
2017
- First: Ji Lin, Zachary M. Thomas, Jingyi Liu & Mythili Koneru, Eli Lilly & Company, A Bayesian Hierarchical Model for Indirect Comparison of Immuno-oncology Drugs
- Second: Zhen Zeng, Meihua Wang, Xinxin Shu & Cong Chen, Merck Research Laboratories, Improving Dose-finding Methods for Early Oncology Combination Trials
- Third: Wijith Munasinghe, Xin Qi & BoTong, Abbvie, Inc, Safe and Faster Way to Reach Maximum Tolerated Dose (MTD) in Phase I Oncology Trials
2016
Student Travel Award for Regulatory-Industry Statistics Workshop
2020
- Zhaohu (Jonathan) Fan, University of Cincinnati Lidner College of Business
- Rupam Bhattacharyya, University of Michigan
- Michael Daniel Cid Lucagbo, University of Maryland, Baltimore County
- Thevaa Chandereng, University of Wisconsin
- Jinyi Zhou, Duke University
- Ariel Chernofsky, Boston University School of Public Health
2019
- Peifeng Ruan, The George Washington University
- Steve B. Ampah, University of Alabama at Birmingham
- Song Zhai, University of California, Riverside
- Meizi Liu, University of Chicago
- Juhyun Kim, University of California, Los Angeles
- Jinyuan Liu, University of California, San Diego
- Xiao Wu, Harvard University
- Weiji Su, University of Cincinnati
- Ryan Thomas Jarrett, University of Cincinnati
- Yizhe Xu, University of Utah
2018
- Yu Cao, Virginia Commonwealth University
- Xiaowu Dai, University of Wisconsin – Madison
- Lin Dong, North Carolina State University
- Jing Li, Indiana University
- Brooke Ann Rabe, University of Arizona
- Di Zhang, University of Pittsburgh
- Heng Zhou, MD Anderson Cancer Center
- Yanhong Zhou, MD Anderson Cancer Center
Best Contributed Paper Award at Joint Statistical Meetings
2019
- First: Devan Mehrotra, Merck & Co, Survival Analysis Using a 5-STAR Approach in Randomized Clinical Trials
- Second: Susan S. Ellenberg, University of Pennsylvania, Emerging Changes in DMC Oversight
- Third: Wenting Cheng, Biogen, Analysis of Multiple Outcome Measures with Applications to Disability Improvement in Multiple Sclerosis
- Honorable Mention: Paul Gallo, Novartis Pharmaceuticals, Implementing Effective DMC Decision-Making in Complex Clinical Trial Designs
- Honorable Mention: Veronica Bunn, Takeda Pharmaceuticals, Flexible Semiparametric Bayesian Hierarchical Model for Basket Trials
- Honorable Mention: Mary Ryan, University of California, Irvine, An Extension of Cohen’s Kappa for Clustered Data and Group Sequential Testing
2018
- First: James Buchanan, Covilance, LLC, Specific Safety Monitoring Tools and How This Will Benefit Drug Safety
- Second: Barbara Hendrickson, AbbVie, Going from the Program Safety Analysis Plan to the Aggregate Safety Analysis Plan
- Third: Lee Kennedy-Shaffer, Harvard University Department of Biostatistics, Sample Size Estimation for Stratified Cluster Randomized Trials with Binary Outcomes
- Honorable Mention: Lothar Tremmel, CSL Behring, Quantitative Regulatory Landscape
- Honorable Mention: Weidong Zhang, Pfizer, Leveraging Omics Biomarker in Early Clinical Trials - Concept, Utility and Impact on Decision Making
2017
- First: Devan Mehrotra, Qian Guan and Zifang Guo, Merck Research Laboratories, A Powerful Learn-And-Confirm Pharmacogenomics Methodology for Randomized Clinical Trials
- Second: Alexia Lasonos, Memorial Sloan Kettering Cancer Center, Measure Differential Treatment Benefit Across Marker Specific Subgroups: The Choice of Outcome Scale
- Third: Brian Wiens and Llya Lipkovich, Aquinox Pharmaceuticals, Inc, Implementing Multiple Imputation in Non-inferiority Clinical Trials
- Honorable Mention: Steven A. Julious and Jo Rothwell, The University of Sheffield, A Review of the Sample Size Calculations of Randomised Controlled Trials Funded by One of the Leading Funders in the UK.
- Honorable Mention: William R. Sones and Jonathan Cook, University of Oxford, Achieving Consensus on Guidance for Specifying the Target Difference in a RCT Sample Size Calculation – DELTA2 Project
2016
- First: Scott Berry, Berry Consultants, Using Little 'Go' Decisions
- Second: Susan Urach, Medical University of Vienna, Multi-Arm Group Sequential Designs with Simultaneous Stopping Rule
- Second: Gerald Hlavin, Medical University of Vienna, An extrapolation Framework to Specify Requirements for Drug Development in Children
- Third: Tobias Mielke, ICON PLC, Interim Timing in Adaptive Two-Stage Dose-Finding Studies: What happens to the Expected Benefit?
- Honorable Mention: Brian Wiens, Allergan, The Role of Multiple Imputation in Noninferiority Trials.
- Honorable Mention: Ming Zhou, Bristol-Myers Squibb, Interim Go/No=Go Decision Making in Clinical Trials with Longitudinal Outcomes
2015
- First: Devan V. Mehrotra, Merck, How to Strengthen Analyses by Dropping Risky Assumptions: Three Examples
- Second: Steven Snapinn, Amgen, Is the Median PFS Difference Meaningful for Assessing Treatment Effect?
- Third: Kristine Broglio, Berry Consultants, A Prospective Bayesian Adaptive Trial with Hierarchical Borrowing from a Prior Single Arm Study
- Third: Noah Simon, University of Washington Department of Biostatistics, Selection Bias in Adaptive Enrichment Designs
- Honorable Mention: Zifang Guo, Merck, Missing Data Analysis in Crossover Studies with Baseline Measurements and Small Sample Sizes
- Honorable Mention: Kunthel By, FDA, Ruling Out a Safety Margin
2014
- First: Devan V. Mehrotra, Merck & Co, More Powerful Analyzes of Crossover Trials with Baseline Measurements
- Second: Scott R. Evans, Harvard School of Public Health, Using Endpoint Data to Analyze Patients Rather Than Patient Data to Analyze the Endpoints
- Third: Sharon Murray, Parexel Ltd & Allison M. Florance, Novartis Oncology, Transitioning from 3+3 to N-CRM at GlaxoSmithKline
- Honorable Mention: Richard Forshee, FDA-Center for Biologics Evaluation and Research, Communicating Benefit-Risk Analysis Results Using Graphics
- Honorable Mention: Michael Hale, Baxalta US Inc, When is Data Transparency Useful?
- Honorable Mention: Jesse Berlin, Johnson & Johnson, Sharing Clinical Trial Data: Recent Experience and Issues Raised
2013
- First: Corine Baayen, H. Lundbeck A/S & Philip Hougaard, Lundbeck, Testing Effect of a Drug Using Multiple Models for the Dose-Response
- Second: Yonghong Gao, US Dept of Health and Human Services, Adaptive Enrichment Design in Clinical Trial
- Third: Min Lin, Sample Size Re-Estimation in Confirmatory Studies, FDA/CBER
- Honorable Mention: Heng Li, FDA/CDRH & Vandana Mukhi, FDA/CDRH, Design Considerations in Testing Superiority and Noninferiority Hypotheses for a Set of Secondary Endpoints
- Honorable Mention: Nelson Lu, FDA/CDRH & Yunling Xu, FDA/CDRH, Statistical Considerations and Approaches on Using OUS Data to Support a Pre-Market Application of Medical Devices
2012
- First: Scott Emerson, University of Washington, Active Control Trials with Adaptive Modification of Margin to Address Nonconstancy
- Second: Jason Connor, Berry Consultants, A Case Study of a Bayesian Adaptive Cardiology Device Trial Leading to Approval
- Third: Steven Julious, University of Sheffield, The ABC Assumptions of Setting a Noninferiority Margin: When the Margin Assumptions Can Be Violated
- Honorable Mention: Ilya Lipkovich, Quintiles, Strategies for Identifying Predictive Biomarkers in Clinical Trials Using Variable Importance
- Honorable Mention: Carl Dicasoli, Vertex Pharmaceuticals, Interim Analysis of Constancy for Noninferiority Testing in Active Controlled Clinical Trials
2011
- First: Christopher Tong, U.S. Department of Agriculture, Concordance Correlation Coefficient Decomposed into the Product of Precision and Accuracy
- Second: Gang Chen, Johnson & Johnson Pharmaceutical R&D, Design and Operational Issues in Clinical Trials with Adaptive Design
- Third: Radha Railkar, Merck & Co, An Overview of Different Methods to Assess Agreement in Early Phase Clinical Trials
- Honorable Mention: Paul Schuette, U.S. Food and Drug Administration/CDER, Confidence Intervals for Binomial Proportions with Applications to Product Safety Signaling in Drug Exposure Registries
2010
- First: Demidenko E
- Second: Stroup W
- Third: Murray SC
- Honorable Mention: Berry D
- Honorable Mention: Jones B
2009
- First: Gould A
- Second: Chuang-Stein C
- Third: Musser B
- Honorable Mention: Hendrix S
2008
- First: Mukhi V
- Second: Hedeker D
- Third: Zhou Y
- Honorable Mention: Bretz F
- Honorable Mention: Sun X
2007
- First: Mehrotra D
- Second: Hendrix S
- Third: Mehta C
- Honorable Mention: Greco W
- Honorable Mention: Naftel D
2006
- First: Not Reported
- Second: Nguyen H
- Third: Remlinger K
2005
- First: Mehrotra D
- Second: Dmitrienko A
- Third: Mallinckrodt C
2004
- First (tied): Mehrotra D & Gennings C
- Third: Devanarayan V
2003
- First: Nguyen H
- Second: Yang P
- Third: Baughman A
2002
- First: Senn S
- Second: Mehrotra D
- Third: Eberly L
2001
- First: Baggerly K
- Second: Wiens B
- Third: Holmgren E
2000
- First: Goldsmith C
- Second: Devanarayan V
- Third: Wiens B
1999
- First: Railkar R
- Second: Bohidar N
- Third: Helms L
1998
- First: Tangen C
- Second: Mehrotra D
- Third: Meier K
Best Contributed Poster Award at Joint Statistical Meetings
2020
- First: “Impact of Direction of Treatment Effect on Composite Time-to-event Endpoint Via Win Ratio Analysis” by Ran Liao, Sujatro Chakladar, Margaret Gamalo (Eli Lilly)
- Second: “Reginal Efficacy Evaluation in Multi-Reginal Clinical Trials Using a Discounting Factor Weighted Z Test” by XuanxuanYu, JianlingBai, Hao Yu, JingweiWu (Nanjing Medical Univ, Univ of South Carolina, Temple Univ)
- Third: “Interim Monitoring in Sequential Multiple Assignment Randomized Trials” by Liwen Wu, Junyao Wang, and Abdus S. Wahed (Univ. of Pittsburg)
2019
- First: Yun Bai (Medtronic PLC), Zengri Wang, Ted Lystig, and Baolin Wu, Statistical methods for equivalency test in oxymetry comparison study
- Second: Holly Hartman (University of Michigan), Matthew Schipper, and Kelley Kidwell, Small Sample Sequential Multiple Assignment Randomized Trials with Continuous Outcomes
- Third: Jessie Gu (Novartis), Estimand and analysis consideration in a Phase III study of CAR-T (BELINDA) with delayed treatment effect
- Honorable Mention: Phebe Kemmer (Eli Lilly), Tianle Hu, Fanni Natanegara, Zachary Thomas, and Himanshu Upadhyaya, A comparison of migraine prevention therapies in the adult versus pediatric populations using a joint Bayesian network meta-analysis model
-
Honorable Mention: Helen Chen (GlaxoSmithKline), Jonathan Haddad, and Xiaowei Wang, Less is More – Adaptive Seamless Phase II/III Design
2018
- First: Tian Chen, Ye Feng, Shu-Pang Huang, Ming Zhou & Ramachandran Suresh, Bristol Myers-Squibb, Determination of Optimal Cut-off Points for Biomarkers in Oncology Research
- Second: Ellen B. Gurary & Joseph Massaro, Boston University Non-Inferiority Margins in Superiority/Non-inferiority Seamless Clinical Trials
- Third: Ronnie Wang, Daoyuan Shi, Huaming Tan, Neal Thomas, Dan Meyer, Pfizer and the University of Connecticut (Shi), Power and Type I Error for Sizing Binomial Endpoints with Unequal Randomization Ratios
2017
- First: Tian Chen, Ye Feng, Shu-Pang Huang, Ming Zhou & Ramachandran Suresh, Bristol Myers-Squibb, Determination of optimal cut-off points for biomarkers in oncology research
- Second: Ellen B. Gurary & Joseph Massaro, Boston University Non-Inferiority Margins in Superiority/Non-inferiority Seamless Clinical Trials
- Third: Ronnie Wang, Daoyuan Shi, Huaming Tan, Neal Thomas, Dan Meyer, Pfizer and the University of Connecticut (Shi) Power and Type I Error for Sizing Binomial Endpoints with Unequal Randomization Ratios
2016
2015
2014
2013
- First: Bo Huang & Neal Thomas, Pfizer Inc, Optimal Designs with Interim Analyses for Randomized Studies with Long-term Time-specific Endpoints
- Second: Richard J. Willke, Ching-Ray Yu, Birol Emir, Kelly H. Zou, Pfizer Inc. & Javier Cabrera, Rutgers University, A Comparison and Integration of Quantile Regression and Finite Mixture Modeling
- Third Place: Kijoeng Nam & Estelle Russek-Cohen, FDA/CBER, Logistic Regression Likelihood Ratio Test Analysis and Harnessing Graphics to Explore Safety Data in the Vaccine Adverse Event Report System (VAERS)
2012
- First: Li Wang & Weihua Tang, Bristol-Myers Squibb, Meta Analysis for All-cause Death for Apixaban vs. Placebo Or Control in SPAF Trials
- Second: Jianing Di, Xin Zhao, Daniel Wang, Ming Lu, & Michael Krams, Janssen Research & Development, Assessing the Cumulative Exposure Response in Alzheimer Disease Studies
- Third: Kelly H. Zou, Ching-Ray Yu, Ye Tan & Martin O. Carlsson, Pfizer Inc, Comparative Effectiveness Research Using Meta-Analysis to Evaluate and Summarize Diagnostic Accuracy
2011
- First: Junxiang Luo & Yongming Qu, Eli Lilly & Company, Comparison of Negative Binomial Regression Models in Analyzing Hypoglycemia Events
- Second: David Kerr & Shannon Grant, Axio Research, Creating a Better, Shorter DMC Report: A Stack of Needles, Not a Needle in a Haystack
- Third: Alexandra I. Barsdorf, Kelly H. Zou, Martin O. Carlsson, & Joseph C. Cappelleri, Pfizer Inc., Methods for Responder Analysis of Patient-Reported Outcomes
2010
- First: Carlsson M
- Second: Zou K
- Third: Zhao Y
2009
- First: Dragomir A
- Second: Zou K
- Third: Gaffney M
2008
- First: Zou K
- Second: Siqueira A
- Third: Coar W
Student Paper Award at Joint Statistical Meetings
2020
- First: Xinzhou Guo, University of Michigan, Inference on Selected Subgroups in Clinical Trials
- Second: Duzhe Wang, University of Wisconsin-Madison, Boosting Algorithms for Estimating Optimal Treatment Rules
- Third: Dana Johnson, North Carolina State University, One-Step Value Difference Test for The Existence of a Subgroup with Beneficial Treatment Effect Using Random Forests
- Honorable Mention: Thevaa Chandereng, University of Wisconsin-Madison, Robust Blocked Response-Adaptive Randomization Designs
2019
- First: Ting Ye, University of Wisconsin-Madison, Validity and robustness of tests in survival analysis under covariate-adaptive randomization
2018
- First: Jiaying Lyu, University of Chicago, AAA: Triple-adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose-finding trials
- Second: David Cheng, Department of Biostatistics, Harvard University, The Statistical Performance of Matching-Adjusted Indirect Comparisons
- Third: Arjun Sondhi, Department of Biostatistics, University of Washington, The Reduced PC-Algorithm: Improved Causal Structure Learning in Large Random Networks
- Honorable Mention: Ting Ye, Department of Statistics, University of Wisconsin-Madison, A Robust Approach to Sample Size Calculation in Cancer Immunotherapy Trials with Delayed Treatment Effect
- Honorable Mention: Kan Li, University of Texas Health Science Center at Houston, Bayesian Personalized Multi-Criteria Benefit-Risk Assessment of Medical Products
2017
- First: Nathaniel O’Connell, Medical University of South Carolina, A latent variable approach to elicit continuous toxicity scores and severity weights for multiple toxicities in dose-finding oncology trials
- Second: Zhengling Qi, University of North Carolina at Chapel Hill, D-learning to estimate optimal individual treatment rules
- Third: Menghan Li, Pennsylvania State University, Joint analysis of left-censored longitudinal biomarker and binary outcome via latent class modeling
- Honorable Mention: Florica Constantine, Johns Hopkins University, A Bayesian adaptive subgroup identification enrichment design
- Honorable Mention: Lie Li, Southern Methodist University, Meta-analysis of rare binary events in treatment groups with unequal variability
2016
- First: Jingxiang Chen, University of North Carolina – Chapel Hill, Estimating Individualized Treatment Rules for Ordinal Treatments
- Second: Ailin Fan, North Carolina State University, Change-Plane Analysis for Subgroup Detection and Sample Size Calculation
- Third: Yiyi Chu, University of Texas , Adaptive Dose Modification for Phase I Clinical Trials
- Honorable Mention: Xin Lu, Emory University, Evaluating the Effect of Delayed PEG Insertion in Patients Diagnosed with ALS via Adaptive Treatment Length Regimens
- Honorable Mention: Geoffrey Johnson, University of Pittsburgh, Optimizing Dynamic Treatment Regimes via Threshold Utility Analysis on Quality Adjusted Lifetime for Subgroup Analysis in Clinical Trials
- Honorable Mention: Susanne Urach, Medical University of Vienna, Multi-arm Group Sequential Designs with Simultaneous Stopping Rule
- Honorable Mention: Soyeon Kim, Rice University, Prediction-Oriented Marker Selection (PROMISE) with application to high-dimensional regression
2015
- First: Ying Liu, Columbia University, Sequential Multiple Assignment Randomization Trials
- Second: Yebin Tao, University of Michigan, Optimal Dynamic Treatment Regimes for Treatment Initiation
- Third: Patrick Schnell, University of Minnesota, A Bayesian Hierarchical Modeling Approach to Identifying Subgroups
- Honorable Mention: Priyam Mitra, Rutgers University, Dose Finding Strategies In Combination Therapy
- Honorable Mention: Lu Mao, University of North Carolina, Semiparametric Proportional Rates Regression
2014
- First: Yanxun Xu, University of Texas at Austin, Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials
- Second: Qing Liu, University of Pittsburgh, Landmark Proportional Subdistribution Hazards Models for Dynamic Prediction of Cumulative Incidence Probabilities
- Third: Lee McDaniel, University of Wisconsin-Madison, Sample Size Under the Additive Hazards Model
- Honorable Mention: Guang Yang, Rutgers University, Meta-analysis of rare events: From combining confidence intervals to combining confidence distributions
- Honorable Mention: Pallavi S. Mishra-Kalyani, Emory University, Propensity Process for Time-varying Covariates with Application to Assessing Treatment Effect in ALS Patients
2013
- First: Jing Zhou, University of North Carolina, Information-Based Sample Size Re-estimation in Group Sequential Design for Longitudinal Trials
- Second: Chen Hu, University of Michigan, A Frailty-based Progressive Multistate Model for Progression and Death in Cancer Studies
2012
- First: Kelley Kidwell, University of Pittsburgh, Weighted Log-rank Statistic to Compare Shared-Path Adaptive Treatment Strategies
- Second: Jonathan Yabes, University of Pittsburgh, Semiparametric Estimation in the Proportional Subdistribution Hazards Model with Missing Cause of Failure
- Third: Chunyan Cai, Texas MD Anderson Cancer Center, Bayesian Adaptive Phase II Screening Design for Combination Trials
- Honorable Mention: Layla Parast, Harvard University, Landmark Estimation of Survival Incorporating Intermediate Event Information in a Randomized Clinical Trial
2011
2010
- First: Zhao S
- Second: Cho Y
2009
2008
2007
2006
- First: Dai H
- Honorable Mention: Spann M
- Honorable Mention: Lewin D
2005
2004
- First: Chen J & McHenry M
- Honorable Mention: Feng S
- Honorable Mention: Wang X
- Honorable Mention: Serban N
2003
- First: Wahed A, Peng X, He W, Remlinger K & Serban N
2002
- First: Johnson B & McNally R
2001
- First: Huang X, Hyslop T, Li L & Song X
2000
- First: Bryan J, Yu D, Somayaji V, Yu Q & Shang Z
1999
- First: Railkar R, Burzykowski T, Tang S & Allen A
The "Stan Altan" Best Nonclinical Biostatistics Paper Award
2023
- 1st Place: Paul Faya, Steven Novick, John W. Seaman Jr., John J. Peterson, Tony Pourmohamad, Dwaine Banton & Yanbing Zheng (2023) Continuous Method Validation: Beyond One-Time Studies to Characterize Analytical Methods, Statistics in Biopharmaceutical Research, 15:1, 225-233
- 2nd Place: Qiao Z, Barnes E, Tringe S, Schachtman DP, Liu P. Poisson hurdle model-based method for clustering microbiome features. Bioinformatics. 2023 Jan 1;39(1):btac782. doi: 10.1093/bioinformatics/btac782. PMID: 36469352; PMCID: PMC9825753.
- 3rd Place: Mallick H, Rahnavard A, McIver LJ, Ma S, Zhang Y, Nguyen LH, Tickle TL, Weingart G, Ren B, Schwager EH, Chatterjee S, Thompson KN, Wilkinson JE, Subramanian A, Lu Y, Waldron L, Paulson JN, Franzosa EA, Bravo HC, Huttenhower C. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput Biol. 2021 Nov 16;17(11):e1009442. doi: 10.1371/journal.pcbi.1009442. PMID: 34784344; PMCID: PMC8714082.
2021
- 1st Place: Burdick, R. K., Thomas, N., & Cheng, A. (2017). Statistical considerations in demonstrating CMC analytical similarity for a biosimilar product. Statistics in Biopharmaceutical Research, 9(3), 249-257.
- 2nd Place: Novick, S. J., Christian, E., Farmer, E., & Tejada, M. (2021). A Bayesian statistical approach to continuous qualification of a bioassay. PDA Journal of Pharmaceutical Science and Technology, 75(1), 8-23.
- 3rd Place: Sondag, P., & Lebrun, P. (2020). Risk-based similarity testing for potency assays using MCMC simulations. Statistics in Biopharmaceutical Research, 1-10.
2019
- Zeng, L., Novick, S., Yu, B., and Yang, H. (2019). “General Framework for Equivalence Testing over a Range of Linear Outcomes with CMC Applications”, Statistics in Biopharmaceutical Research, 11(2), 182-190.
2017
- Zhang, J., Li, W., Roskos, L, and Yang H. (2017). “Immunogenicity assay cut point determination using nonparameteric tolerance limit”, Journal of Immunological Methods, 442, 29-34.
2015
- Novick, S., Shen, Y., Yang, H., Peterson, J., LeBlond, D., and Altan, S. (2015). “Dissolution Curve Comparisons through the F2 Parameter, a Bayesian Extension of the f2 Statistic”, Journal of Biopharmaceutical Statistics, 25(2), 351-371.Bottom of Form
- Chen, G., Zhong, H., Belousov, A., and Devanarayan, V. (2015). “A PRIM Approach to Predictive-signature Development for Patient Stratification”, Statistics in Medicine, 34, 317–342.
NCB Conference Best Student Poster Award
2023
- 1st Place: Yajie Duan (Rutgers University), “A Novel Two-stage Deming Regression Model with applications to Multiple Risks Assessment”
- 2nd Place: Sofia Prieto Leon (Hasselt University), “Covariate-driven dimensionality reduction methods for sc-RNA seq studies”
2021
- 1st Place: Louise Leonard, “Tackling Missing Values in Mass Spectrometry-based Data”
- 2nd Place: Jinghang Lin, “Expectile Neural Networks for Genetic Data Analysis of Complex Diseases”
2019
- Winner: Perceval Sondag, "Risk-based Parallelism Test for Parallel Curve Assays"
2017
- Yalin Zhu (NJIT), FWER controlling multiple testing procedures for discrete data in clinical safety analysis
- Han Ding Xie (Rutgers), Time Courses and Predictors of Readmissions or Death Among Patients Who Were Discharged Alive with a First Diagnosis of Heart Failure in a New Jersey Statewide Database
2015
- Winner: Andrew Gehman (Temple U.), Approaches and Challenges in Estimating Multivariate Random Components from a Fractional Factorial Experiment"
2013
- Discovery: Gavin Lynch (NJIT), On Procedures Controlling the False Discovery Rate for Testing Hierarchically Ordered Hypotheses
- Discovery: Jacqueline Hughes-Oliver (George Mason University & NC State), Mining in the Presence of Class Imbalance: Precision-Recall Curves and the F-Measure
- Pre-clinical: Ada Youk (University of Pittsburgh), Time-dependent measures in a benefit-risk assessment of drug exposure using pharmacy claims
Return to Top